Key Takeaways
- • Oura plans to raise up to $2.2 billion through a U.S. IPO, pricing 50 million shares at $40 to $44 per share, implying a valuation of up to $14.1 billion at the top end of the range.
- • The IPO valuation represents a 28% premium over Oura's $11 billion Series E valuation in 2025, reflecting investor confidence in the wearable health-tech sector despite current profitability challenges.
- • Oura reported a net loss of $924.3 million on $1.21 billion in revenue for the nine-month period ended June 30, 2026, demonstrating the company's significant cash burn while scaling operations.
- • The company has reached 5 million paid members for its Oura Membership subscription service, a key metric indicating recurring revenue potential and customer retention in the competitive health wearables market.
Summary
Oura, the Finnish smart ring manufacturer, is pursuing a U.S. initial public offering with a target raise of up to $2.2 billion, according to Bloomberg. The company plans to offer 50 million shares priced between $40 and $44 per share, a valuation framework that could place the company at up to $14.1 billion at the high end of the range.
The IPO represents a significant step forward for Oura following its Series E financing round in 2025, when the company achieved an $11 billion valuation. The proposed public market valuation signals a 28% premium, suggesting sustained investor appetite for wearable health technology despite the company's current path to profitability. The pricing range reflects confidence in Oura's business model and market positioning within the health-monitoring device category.
Oura's financial performance reveals the capital intensity of its business model. For the nine-month period ended June 30, 2026, the company reported $1.21 billion in revenue against a net loss of $924.3 million. This substantial operating loss underscores the investments required to scale manufacturing, expand its user base, and develop proprietary health analytics technology. However, the company has demonstrated traction on the subscriber front, with its Oura Membership service reaching 5 million paid members, establishing a foundation for recurring revenue streams that could improve profitability at scale.
The IPO positions Oura to accelerate product development, expand its commercial infrastructure, and potentially pursue strategic acquisitions in adjacent health-tech categories. For institutional investors evaluating exposure to the wearable health technology sector, Oura's public market entry offers a direct play on growing consumer demand for non-invasive health monitoring, though investors should weigh the company's current unprofitability against its revenue growth trajectory and subscriber expansion metrics.
The IPO represents a significant step forward for Oura following its Series E financing round in 2025, when the company achieved an $11 billion valuation. The proposed public market valuation signals a 28% premium, suggesting sustained investor appetite for wearable health technology despite the company's current path to profitability. The pricing range reflects confidence in Oura's business model and market positioning within the health-monitoring device category.
Oura's financial performance reveals the capital intensity of its business model. For the nine-month period ended June 30, 2026, the company reported $1.21 billion in revenue against a net loss of $924.3 million. This substantial operating loss underscores the investments required to scale manufacturing, expand its user base, and develop proprietary health analytics technology. However, the company has demonstrated traction on the subscriber front, with its Oura Membership service reaching 5 million paid members, establishing a foundation for recurring revenue streams that could improve profitability at scale.
The IPO positions Oura to accelerate product development, expand its commercial infrastructure, and potentially pursue strategic acquisitions in adjacent health-tech categories. For institutional investors evaluating exposure to the wearable health technology sector, Oura's public market entry offers a direct play on growing consumer demand for non-invasive health monitoring, though investors should weigh the company's current unprofitability against its revenue growth trajectory and subscriber expansion metrics.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.